AstraZeneca PLC (OTCMKTS:AZNCF) Sees Large Growth in Short Interest

AstraZeneca PLC (OTCMKTS:AZNCF) was the target of a large growth in short interest in September. As of September 15th, there was short interest totalling 42,100 shares, a growth of 352.7% from the August 31st total of 9,300 shares. Based on an average trading volume of 2,800 shares, the days-to-cover ratio is currently 15.0 days.

Institutional Investors Weigh In On AstraZeneca

An institutional investor recently bought a new position in AstraZeneca stock. Kennedy Capital Management LLC bought a new stake in shares of AstraZeneca PLC (OTCMKTS:AZNCF) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 37,554 shares of the company’s stock, valued at approximately $5,068,000. 40.87% of the stock is owned by hedge funds and other institutional investors.

AstraZeneca Trading Down 3.7 %

Shares of OTCMKTS:AZNCF traded down $5.80 during midday trading on Wednesday, reaching $149.34. 6,361 shares of the company’s stock traded hands, compared to its average volume of 2,880. AstraZeneca has a one year low of $118.16 and a one year high of $175.00. The stock has a 50 day moving average of $162.63 and a 200 day moving average of $152.89.

AstraZeneca Cuts Dividend

The business also recently declared a dividend, which was paid on Monday, September 9th. Stockholders of record on Friday, August 9th were issued a dividend of $1.00 per share. The ex-dividend date was Wednesday, August 7th. AstraZeneca’s payout ratio is presently 343.14%.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.